Our Mission
As an innovative human biologics company, our mission is to help patients overcome inflammation driven diseases, from infancy to old age, using regenerative biotherapeutics.
Vision
We share the vision of becoming the global leader in the commercialization of safe and effective birth tissue biotherapeutics for treating and preventing inflammation driven diseases.
Behind Our Science
We are dedicated to creating innovative solutions for the most complex medical challenges, utilizing our unique approach to regenerative medicine. Plakous has developed a human placental extract (HPE), a biologic with anti-inflammatory and cellular proliferation capabilities that work together to orchestrate a complex cellular response to restore and repair organs damaged by inflammation-driven diseases. (Footnote: Data on file. Plakous Therapeutics.)
Value of HPE
Necrotizing Enterocolitis (NEC): Pre-clinical Efficacy
Plakous has received rare pediatric and orphan drug designations for its potential in preventing NEC disease, and our preclinical work has shown significant decreases in disease severity and the number of gut segments affected.
Pediatric Malabsorption: Development of Immature Digestive Organs
In preclinical models of extreme prematurity, HPE has shown statistical increases in weight gain.
News
Journal Article Published
The devastation caused by necrotizing enterocolitis (NEC) has continued to claim the lives of infants despite advances in neonatal medicine. To address the acute, and often se…
Read More
NIH Funding Renewal
Plakous Therapeutics, Inc. completed year 1 of our recently awarded Phase IIB Small Business Innovation Research (SBIR) grant providing up to $2,925,000 from the Eunice Kenned…
Read More
New Board Member
Plakous Therapeutics, Inc. is excited to announce the addition of James Kalinovich to its Board of Directors. James brings strong financial expertise with 30 years in corporat…
Read MoreContact Us
Our expert team can help answer any questions you may have.
Get in touch today to learn more about Plakous Therapeutics.
References: